- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04403165
Locus-coeruleus Function in Normal Elderly and AD Risk (LEAD)
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.
Study Overview
Status
Conditions
Detailed Description
The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine Mount Sinai
-
New York, New York, United States, 10016
- NYU Grossman School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
- Subjects will be within normal limits on neurological and psychiatric examinations.
- All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
- All subjects will have had a minimum of 12 years of education.
Exclusion Criteria:
- History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
- Significant history of alcoholism or drug abuse.
- Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
- Geriatric Depression Scale (short form)>6.
- Insulin dependent diabetes.
- Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
- Physical impairment of such severity as to adversely affect the validity of psychological testing.
- Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
- History of a first-degree family member with early onset (age <60 years) dementia.
- Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
- Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
- Failure to complete all study visit within 4 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitively Normal (CN) Older Adults
|
Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics. Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio. PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability. Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Time Frame: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
|
|
Total Rapid Eye Movement (REM) Duration (Min)
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of Time Spent in REM Sleep
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of REM Runs That Are Less Than 5 Minutes
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of Correct Responses on the Picture Test
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Picture Test Response Time
Time Frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Levels of Hyperphosphorylated Tau (P-Tau)
Time Frame: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Levels will be derived from the plasma and reported in pg/mL |
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ricardo Osorio, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurocognitive Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- Alzheimer Disease
- Investigative Techniques
- Therapeutics
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Biopsy
- Diagnostic Techniques, Neurological
- Spinal Puncture
Other Study ID Numbers
- 20-00002
- 1R21AG067549-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All of the individual participant data collected during the trial, after deidentification.
IPD Sharing Time Frame
Immediately following publication. No end date.
IPD Sharing Access Criteria
The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.